Akorn gets FDA nod for generic Flonase

Press enter to search
Close search
Open Menu

Akorn gets FDA nod for generic Flonase

By Sandra Levy - 08/27/2019
Akorn has received the Food and Drug Administration's clearance for azelastine hydrochloride nasal spray, 0.15%.

The product is the generic of GSK's Flonase.

It is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 6 years of age and older and perennial allergic rhinitis in patients 6 years of age and older.

Azelastine hydrochloride nasal spray, 0.15% had a market value of roughly $18 million for the 12 months ended June 2019, according to IQVIA.

Related Topics